Serotonin 5-HT(2C) agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens

Brain Research

Volumn 781, Issue 1-2, 1998, Pages 291-299

  Willins, David L ^a,c   Meltzer, Herbert Y ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cocaine; Dopamine; Microdialysis; Morphine; Nucleus accumbens; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; AMPEROZIDE; COCAINE; DOPAMINE; MORPHINE; SEROTONIN 2C AGONIST; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; NARCOTIC ANTAGONIST; PIPERAZINE DERIVATIVE; PYRAZINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; SPRAGUE DAWLEY RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; AMPHETAMINES; ANIMALS; COCAINE; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; MALE; MICRODIALYSIS; MORPHINE; NARCOTIC ANTAGONISTS; NUCLEUS ACCUMBENS; PIPERAZINES; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0032545531     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01267-5     Document Type: Article

References (53)

1. 1c receptors in rat brain. J. Pharmacol. Exp. Ther. 255:1990;843-857.
2. Axelsson R., Nilsson A., Christensson E., Björk A. Effects of amperozide in schizophrenia. Psychopharmacology. 104:1991;287-292.
3. Bradberry C.W., Roth R.H. Cocaine increases extracellular dopamine in rat nucleus accumbens and ventral tegmental area as shown by in vivo microdialysis. Neurosci. Lett. 103:1989;97-102.
4. 3 antagonist on drug-induced stimulation of dopamine release. Eur. J. Pharmacol. 164:1989;515-519.
5. Clineschmidt B.V. MK-212: a serotonin-like agonist in the CNS. Gen. Pharmacol. 10:1979;287-290.
6. Crespi F., Garret J.C., Sleight A.J., Marsden C.A. In vivo evidence that 5-HT neuronal firing rate and release are not necessarily correlated with 5-HT metabolism. Neuroscience. 35:1990;139-144.
7. De Montigny C., Blier P., Chaput Y. Electro-physiologically-identified serotonin receptors in the rat CNS. Neuropharmacology. 23:1984;1511-1520.
8. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85:1988;5274-5278.
9. Di Chiara G., North A. Neurobiology of opiate abuse. Trends Pharmacol. Sci. 13:1992;185-193.
10. 3H]-dopamine in vitro from perfused rat striatal and limbic brain areas. Pharmacol. Toxicol. Suppl. 66:1990;45-48.
11. Fibiger H.C. Drugs and reinforcement mechanisms: a critical review of the catecholamine theory. Ann. Rev. Pharmacol. Toxicol. 18:1978;37-56.
12. Garratt J.C., Kidd E.J., Marsden C.A. Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist, DOI. Eur. J. Pharmacol. 199:1991;349-355.
13. Glennon R.A., Raghupathi R., Bartyzel P., Teitler M., Leonhardt S. Binding of phenyalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem. 35:1992;734-740.
14. Grenhoff J., Tung C.S., Ugedo L., Svensson T.H. Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol. Toxicol. 66:1990;29-33.
15. Guan X.M., McBride W.J. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res. Bull. 23:1989;541-547.
16. Gustafsson B., Christensson E. Amperozide - a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behavior. Pharmacol. Toxicol. 66(Suppl. 1):1990;12-17.
17. Gysling K., Wang R.Y. Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res. 277:1983;119-127.
18. 1C receptors. Trends Pharmacol. Sci. 9:1988;89-94.
19. Ichikawa J., Meltzer H.Y. Amperozide, a novel antipsychotic drug, inhibits the ability of D-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J. Neurochem. 58:1992;2285-2291.
20. Ichikawa J., Meltzer H.Y. DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res. 698:1995;204-208.
21. Johanson C.E., Fischman M.W. The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 41:1989;3-52.
22. Kalivas P.W., Duffy P., Eberhardt H. Modulation of A10 dopamine neurons by γ-aminobutyric acid agonists. J. Pharmacol. Exp. Ther. 253:1990;858-866.
23. Kimura K., Nomikos G.G., Svensson T.H. Effects of amperozide on psychostimulant-induced hyperlocomotion and dopamine release in the nucleus accumbens. Pharmacol. Biochem. Behav. 44:1993;27-36.
24. Klitenick M.A., DeWitte P., Kalivas P.W. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study. J. Neurosci. 12:1992;2623-2632.
25. 3H catecholamine uptake by rat brain synaptosomes. Life Sci. 21:1977;1117-1122.
26. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
27. R. Kuzcenski, Biochemical actions of amphetamine and other stimulants, in: I. Creese (Ed.), Stimulants: neurochemical, behavioral and clinical perspectives, Raven Press, New York, 1983, pp. 31-61.
28. Marcus M.M., Nomikos G.G., Svensson T.H. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur. Neuropsychopharmacol. 6:1996;29-38.
29. Matthews R.T., German D.C. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience. 11:1984;617-625.
30. 3 antagonist zacopride attenuates cocaine-induced increases in extracellular dopamine in rat nucleus accumbens. Pharmacol. Biochem. Behav. 45:1993;759-763.
31. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
32. 2 receptor occupancy: implications for antipsychotic action. Eur. J. Pharmacol. 216:1992;67-71.
33. Moore R.Y., Halaris A.E., Jones B.E. Serotonin neurons in the midbrain raphé: ascending projections. J. Comp. Neurol. 180:1978;417-438.
34. 1a receptors in the dorsal raphé nucleus of the guinea pig. Neurosci. Lett. Suppl. 42:1992;S33.
35. Nestler E.J. Molecular mechanisms of drug addiction. J. Neurosci. 12:1992;2439-2450.
36. Nomikos G.G., Iurlo M., Andersson J.L., Kimura K., Svensson T.H. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology-Berl. 115:1994;147-156.
37. 3H]5-Hydroxytryptamine. Neuroscience. 6:1981;115-138.
38. Parsons L.H., Justice J.B. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res. 606:1993;195-199.
39. G. Paxinos, C. Watson, The rat brain in stereotaxic coordinates, Academic Press, New York (1992).
40. Pazos A., Cortés R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain: II. Serotonin-2 receptors. Brain Res. 346:1985;231-249.
41. 3 antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur. J. Pharmacol. 230:1993;63-68.
42. Philipson O.T. Afferent projections to ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J. Comp. Neurol. 187:1979;117-144.
43. Pitts D.K., Marwah J. Cocaine and central monoaminergic neurotransmission: a review of electrophysiological studies and comparison to amphetamine and antidepressants. Life Sci. 42:1988;949-968.
44. 2C receptors. Mol. Brain Res. 23:1994;163-178.
45. Prisco S., Pagannone S., Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J. Pharmacol. Exp. Ther. 271(1):1994;83-90.
46. Ross S.B., Renzi A.L. Inhibition of the uptake of tritiated catecholamines by antidepressant and related agents. Eur. J. Pharmacol. 2:1967;181-186.
47. 1c receptors. J. Pharm. Exp. Ther. 260:1992;1361-1365.
48. Svartengren J., Simonsson P. Receptor binding properties of amperozide. Pharmacol. Toxicol. 66:1990;8-11.
49. Van Bockstaele E.J., Cestari D.M., Pickel V. Synaptic structure and connectivity of serotonin terminals in the ventral tegmental area: potential sites for modulation of mesolimbic dopamine neurons. Brain Res. 647:1994;307-322.
50. Wise R., Bozarth M. Actions of drugs of abuse on brain reward systems: an update with specific attention to opiates. Pharmacol. Biochem. Behav. 17:1982;239-243.
51. 2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphé nucleus and 5-HT release and metabolism in the frontal cortex. Brain J. Pharmacol. 99:1990;221-222.
52. Yamamoto B.K., Meltzer H.Y. The effect of the atypical antipsychotic drug, amperozide, on carrier-mediated striatal dopamine release measured in vivo. J. Pharmacol. Exp. Ther. 263:1992;180-185.
53. Yarbrough G.G., Singh D.K., Pettibone D.J. A comparative electrophysiological and biochemical assessment of serotonin (5-HT) and a novel 5-HT agonist (MK-212) on central serotonergic receptors. Neuropharmacology. 23:1984;1271-1277.